These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35936702)

  • 1. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
    Chen T; Xie R; Zhao Q; Cai H; Yang L
    Front Oncol; 2022; 12():746526. PubMed ID: 35936702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
    Shao T; Ren Y; Zhao M; Tang W
    Front Public Health; 2022; 10():912921. PubMed ID: 36045725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy vs. Chemotherapy Alone as the First-Line Treatment in Patients With IIIB-IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China.
    Zhu C; Xing XX; Wu B; Liang G; Han G; Lin CX; Fang HM
    Front Pharmacol; 2021; 12():735536. PubMed ID: 35002693
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
    Dai H; Wang W; Fan X; Chen Y
    Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China.
    Qiao L; Zhou Z; Zeng X; Tan C
    Front Pharmacol; 2021; 12():728440. PubMed ID: 34795580
    [No Abstract]   [Full Text] [Related]  

  • 7. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
    Huo G; Liu W; Kang S; Chen P
    Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
    Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
    Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
    Liu H; Wang Y; He Q
    Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
    Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
    J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
    Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
    Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma.
    Gong J; Shang J; Su D; Qian X; Liu G; Sun Z
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):709-717. PubMed ID: 37190977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.
    Zhao Z; Chen T; Zhou Z; Guo R; Liu Q
    BMJ Open; 2023 Dec; 13(12):e071832. PubMed ID: 38110377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
    Chen X; Zhao M; Tian L
    Front Pharmacol; 2023; 14():1119906. PubMed ID: 37021058
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Camrelizumab
    Zhang Q; Wu P; He X; Ding Y; Shu Y
    Front Oncol; 2021; 11():790373. PubMed ID: 34926306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
    Shu Y; Ding Y; Li F; Zhang Q
    Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
    Zheng Z; Zhu G; Cao X; Cai H; Zhu H
    Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.